ADOPT data not major setback for Eliquis from BMS/Pfizer

Eliquis (apixaban), Bristol-Myers Squibb/Pfizer's new oral direct Factor Xa inhibitor anticoagulant, has failed to show superiority to the standard of care low molecular weight heparin enoxaparin (Sanofi's Lovenox/Clexane) in preventing venous thromboembolism in a Phase III trial in patients with acute medical illness.